B+
Bull case
20%
Probability
Target price
$4.25
Analysis reference price unavailable
Analysis 2026-08-05 · RankAlpha Sentiment Codex
NTRB
NutribandFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$2.30
Analysis reference price unavailable
Analysis 2026-08-05 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-08-05 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-05
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Primary-source context is materially stronger than current news flow, but the evidence is mainly filing-based and forward milestones remain undated. No reliable direct operating peer set was identified; social context, options data, short interest, and employee sentiment are unavailable. The deterministic signal is negative, supporting cautious monitoring rather than a bullish conclusion.
RankAlpha Sentiment Codex - 2026-08-05
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-11-03catalystFinancing supports near-term development runwayHigh impact
The amended three-year facility may support continued regulatory and manufacturing preparation, but it is debt financing rather than evidence of approval, revenue acceleration, or commercial demand. Estimated monitoring window uses the conservative 90-day rule [#8-K-2026-06-22].
2027-08-05catalystAVERSA Fentanyl FDA-to-manufacturing executionHigh impact
An amended $5 million credit line is intended to finance AVERSA Fentanyl through the FDA approval process and into commercial-scale manufacturing. No approval, regulatory milestone, or commercialization date is disclosed, so this remains a speculative long-term catalyst [#8-K-2026-06-22].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-05 • Updated nightlySource: Internal modelMethodology